Exchange: NASDAQ·Updated 07:30 PM EST

CDXS News

News
all
press releases
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -28.57% and -43.80%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -28.57% and -43.80%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +56.67% and +116.10%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Revolution Medicines (RVMD) delivered earnings and revenue surprises of +18.80% and +596.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Codexis (CDXS) delivered earnings and revenue surprises of +23.53% and +17.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
ANI (ANIP) delivered earnings and revenue surprises of +9.95% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +21.50% and +18.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
AC Immune (ACIU) delivered earnings and revenue surprises of +113.64% and +1,812.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Codexis stock falls after hours after pricing a discounted public offering. Here's why CDXS shares are moving today.read more...
Benzinga

Advertisement|Remove ads.